Evidence Shows Vitamin D Helps Slow Cancer Cells
 |
November 26, 2012
By: Lee Rannals : courtesy of redOrbit.com
McGill University researchers have discovered vitamin D helps to slow the progression of cells of cancer from premalignant to malignant states.
The researchers reported in the journal Proceedings of the National Academy of Sciences vitamin D helps to inhibit both the production and function of the protein cMYC, which drives cell division and is active at elevated levels in more than half of all cancers.
Vitamin D has been known to have a wide range of physiological effects. Scientists have understood that a correlation exists between insufficient amounts of vitamin D and increased incidence of a number of cancers.
The correlations between the vitamin and cancers are strong for those cancers of the digestive tract, including colon cancer and certain forms of leukemia.
“For years, my lab has been dedicated to studying the molecular mechanisms of vitamin D in human cancer cells, particularly its role in stopping their proliferation,” Professor John White of the Faculty of Medicine’s Department of Physiology, said in a statement.
Vitamin D can be obtained from limited dietary sources as well as from direct exposure to the sun during the spring and summer months. Having a lack of exposure to the sun, mixed with a combination of poor dietary intake, has created vitamin D deficiency or insufficiency in large populations around the world. White said the team discovered vitamin D controls both the rate of production and the degradation of cMYC. They also found it strongly stimulates the production of a natural antagonist of cMYC known as MXD1, which shuts down cMYC function.
For the study, the researchers applied vitamin D to the skin of mice and observed a drop in the level of cMYC, discovering evidence of a decrease in its function. They also found strongly elevated levels of cMYC in a number of tissues, including skin and the lining of the colon.
“Taken together, our results show that vitamin D puts the brakes on cMYC function, suggesting that it may slow the progression of cells from premalignant to malignant states and keep their proliferation in check,” White said in the statement.
He said the team hopes the study will encourage people to maintain adequate vitamin D levels. Also, he said they hope the results will stimulate the development of large trials to test the effects of adequate supplementation.
McGill University researchers have discovered vitamin D helps to slow the progression of cells of cancer from premalignant to malignant states.
The researchers reported in the journal Proceedings of the National Academy of Sciences vitamin D helps to inhibit both the production and function of the protein cMYC, which drives cell division and is active at elevated levels in more than half of all cancers.
Vitamin D has been known to have a wide range of physiological effects. Scientists have understood that a correlation exists between insufficient amounts of vitamin D and increased incidence of a number of cancers.
The correlations between the vitamin and cancers are strong for those cancers of the digestive tract, including colon cancer and certain forms of leukemia.
“For years, my lab has been dedicated to studying the molecular mechanisms of vitamin D in human cancer cells, particularly its role in stopping their proliferation,” Professor John White of the Faculty of Medicine’s Department of Physiology, said in a statement.
Vitamin D can be obtained from limited dietary sources as well as from direct exposure to the sun during the spring and summer months. Having a lack of exposure to the sun, mixed with a combination of poor dietary intake, has created vitamin D deficiency or insufficiency in large populations around the world. White said the team discovered vitamin D controls both the rate of production and the degradation of cMYC. They also found it strongly stimulates the production of a natural antagonist of cMYC known as MXD1, which shuts down cMYC function.
For the study, the researchers applied vitamin D to the skin of mice and observed a drop in the level of cMYC, discovering evidence of a decrease in its function. They also found strongly elevated levels of cMYC in a number of tissues, including skin and the lining of the colon.
“Taken together, our results show that vitamin D puts the brakes on cMYC function, suggesting that it may slow the progression of cells from premalignant to malignant states and keep their proliferation in check,” White said in the statement.
He said the team hopes the study will encourage people to maintain adequate vitamin D levels. Also, he said they hope the results will stimulate the development of large trials to test the effects of adequate supplementation.
*****
|
nutraMetrix Isotonix® Vitamin D with K2
What Makes nutraMetrix Isotonix® Vitamin D with K2 Unique?
nutraMetrix
Isotonix Vitamin D with K2 contains vitamin D3, the metabolically
active form of vitamin D, along with vitamin K2, a form of vitamin K
which supports vascular health and calcium utilization. Vitamin D plays
an important role in bone health, heart health and immune support, while
working with vitamin K to support normal absorption of calcium and
promote healthy arteries. nutraMetrix Isotonix Vitamin D is the first of
its kind to deliver both of these powerful vitamins with isotonic
delivery.
Vitamin
K is included in nutraMetrix Isotonix Vitamin D with K2 because of its
unique partnership with vitamin D. Vitamins K and D work together to
support calcium absorption and utilization. Vitamin K supports the
normal delivery of calcium to the bones and promotes healthy arteries.
At
least two naturally-occurring forms of vitamin K have been identified
and are known as K1 and K2. While there are many similarities between
these two forms of vitamin K, they are distinguished by their important
differences. The most significant difference between K1 and K2 is their
chemical structure which results in different pharmacokinetic
properties. Vitamin K1 is retained primarily in the liver where, at high
doses, it may interfere with the action of warfarin and other
anticoagulant medications.
Vitamin
K2 has a different mechanism of action. It is transported primarily to
bones and blood vessels. Vitamin K2 helps to maintain bone mass, support
calcium utilization and promote elasticity of blood vessels.
Some
studies have concluded that vitamin K2 does not interfere with
anticoagulant medications.* However, most products containing vitamin K
(including K1 and/or K2) warn users taking anticoagulants not to take
the product. If you are currently taking warfarin or another
anticoagulant medication, you should consult your physician before
taking any product containing vitamin K1 or K2.
Isotonix
dietary supplements are delivered in an isotonic solution. This means
that the body has less work to do to obtain maximum absorption of the
nutrients. The isotonic state of the suspension allows nutrients to pass
directly into the small intestine and rapidly absorb into the
bloodstream. With Isotonix products, little nutritive value is lost,
making the absorption of nutrients highly efficient while delivering
maximum results.
Orlampa Enterprises is an internet based product broker specializing in personalized health and wellness related services. Orlampa Enterprises is primed to continue its growth by duplicating its successful business model of educating, training, and developing entrepreneurial leaders as business partners. As an Unfranchise™ business owner, Orlampa Enterprises, proudly utilizes highly researched products including nutraMetrix® nutritional supplements. Contact Beth at bb@orlampa.com or 727.492.8212 for more information about nutraMetrix® partnership opportunities available. |
No comments:
Post a Comment